Browsed by
Tag: price

Apple iPhone 12 lineup: price, specs, release date

Apple iPhone 12 lineup: price, specs, release date

When you buy through our links, we may earn money from our affiliate partners. Learn more.

Apple iPhone October event iPhone 12


Apple iPhone 12 5G October event

The iPhone 12.


The iPhone 12 is the successor to last year’s iPhone 11. Like the iPhone 11, the iPhone 12 has a dual camera and comes in an array of colors: This year’s lineup includes black, white, red, green, and blue. 

But the new device differs from than last year’s model in a few key ways. While the iPhone 11 had the rounded design Apple has employed since the iPhone 6, the iPhone 12 has a sharper edge similar to older iPhones like the iPhone 4 and the new iPad Pro. Apple says the iPhone 12 is 11% thinner and 16% lighter than the iPhone 11.

Unlike the iPhone 11, the new device will also be 5G enabled and will have a 6.1-inch OLED display (last year’s model had Apple’s liquid retina display). Apple says the iPhone 12 has four times better drop performance thanks to a new step in the glass-making process called ceramic shield. 

The iPhone 12 will run on Apple’s new A14 Bionic chip, which Apple says will provide increased performance with better energy efficiency. 

While last year’s version had wireless charging, Apple added a new way to make wireless charging easier with the iPhone 12: the phone will have MagSafe built in, meaning that any MagSafe accessory will automatically snap to the back of the device which should make it easier to wirelessly charge.

The iPhone 12 will start at $799. It will be available to preorder on October 16 and will ship on October 23.

Apple iPhone 12 Mini October event

The iPhone 12 Mini.


The iPhone 12 Mini will contain all of the same specs as the iPhone 12, but in a smaller size — rather than a 6.1-inch OLED

Read the rest
Pachama: Carbon-credit startup puts a price on trees, market opportunity

Pachama: Carbon-credit startup puts a price on trees, market opportunity

  • Backed by Amazon and a fund led by Bill Gates, Pachama runs a marketplace for forest carbon credits. 
  • Carbon credits are generated when a forest is conserved or restored. 
  • As more companies pledge to reduce or eliminate their emissions, the market for carbon credits is expected to surge. 
  • Researchers challenge the efficacy of carbon credits for curbing deforestation and reducing global emissions.
  • For more stories like this, sign up here for our weekly energy newsletter.

In late August, a forest fire, set by lightning and emboldened by climate change, whipped across the Santa Cruz Mountains in California, ultimately burning more than 85,000 acres. 

Diego Saez Gil’s home was among its victims. 

Ironically, it was in that home that Saez Gil dreamt up the idea for his startup, Pachama. Founded in 2018, the company aims to fight climate change — which makes wildfires more common and severe — by protecting forests.

“It is meaningful that now my house is taken by the consequences of climate change, and that those forests will need restoring soon,” Saez Gil, the company’s cofounder, wrote on Medium the day after his home was destroyed. “You can’t make our mission more personal to me now.” 

Click here to subscribe to Insider Energy, Business Insider’s weekly energy newsletter.

Saez Gil’s startup is a tech company, but it’s not your typical Silicon Valley startup.

Pachama sells carbon credits, which represent the carbon dioxide that trees remove from the air. Forests that are protected or restored can generate credits, and companies can buy them to offset their own emissions.

The idea is that, in doing so, businesses can help curb deforestation while reducing their overall climate footprint. 

Though Pachama is just a few years old, it’s won backing from major investors including Bill Gates’ Breakthrough Energy Ventures, Amazon, and tennis

Read the rest
Would Shareholders Who Purchased Infinity Pharmaceuticals’ (NASDAQ:INFI) Stock Five Years Be Happy With The Share price Today?

Would Shareholders Who Purchased Infinity Pharmaceuticals’ (NASDAQ:INFI) Stock Five Years Be Happy With The Share price Today?

It is a pleasure to report that the Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) is up 42% in the last quarter. But will that repair the damage for the weary investors who have owned this stock as it declined over half a decade? Probably not. Like a ship taking on water, the share price has sunk 87% in that time. The recent bounce might mean the long decline is over, but we are not confident. The real question is whether the business can leave its past behind and improve itself over the years ahead.

We really feel for shareholders in this scenario. It’s a good reminder of the importance of diversification, and it’s worth keeping in mind there’s more to life than money, anyway.

Check out our latest analysis for Infinity Pharmaceuticals

We don’t think Infinity Pharmaceuticals’ revenue of US$1,438,000 is enough to establish significant demand. This state of affairs suggests that venture capitalists won’t provide funds on attractive terms. As a result, we think it’s unlikely shareholders are paying much attention to current revenue, but rather speculating on growth in the years to come. For example, they may be hoping that Infinity Pharmaceuticals comes up with a great new product, before it runs out of money.

We think companies that have neither significant revenues nor profits are pretty high risk. There is almost always a chance they will need to raise more capital, and their progress – and share price – will dictate how dilutive that is to current holders. While some such companies do very well over the long term, others become hyped up by promoters before eventually falling back down to earth, and going bankrupt (or being recapitalized). Infinity Pharmaceuticals has already given some investors a taste of the bitter losses that high risk investing can cause.

Infinity Pharmaceuticals

Read the rest
Price Over Earnings Overview: Alexion Pharmaceuticals

Price Over Earnings Overview: Alexion Pharmaceuticals

In the current market session, Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) is trading at $122.80, after a 0.3% drop. However, over the past month, the stock increased by 16.54%, and in the past year, by 21.17%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session.

Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 3.10%.

The P/E ratio is used by long-term shareholders to assess the company’s market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.

Most often, an industry will prevail in a particular phase of a business cycle, than other industries.

Alexion Pharmaceuticals Inc. has a better P/E ratio of 32.84 than the aggregate P/E ratio of 16.56 of the Biotechnology industry. Ideally, one might believe that Alexion Pharmaceuticals Inc. might perform better in the future than it’s industry group, but it’s probable that the stock is overvalued.

P/E ratio is not always a great indicator of the company’s performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.

© 2020 Benzinga does not provide investment advice. All rights reserved.

Source Article Read the rest

ANALYSIS-Israel’s second lockdown carries a hefty economic price

ANALYSIS-Israel’s second lockdown carries a hefty economic price

By Maayan Lubell, Tova Cohen and Steven Scheer

JERUSALEM/TEL AVIV, Oct 8 (Reuters)Restaurateur Tamir Barelko has had enough.

Israel’s decision last month to impose a second nationwide lockdown after a resurgence in coronavirus infections has dealt a hammer blow to the economy and the livelihoods of small business owners, Barelko says.

He launched a petition calling for small businesses to defy the lockdown and reopen from Sunday, the end of the Jewish holiday season, and has attracted more than 60,000 supporters for his campaign on Facebook FB.O over the past two weeks.

The finance ministry and central bank support reopening offices of companies that can avoid face-to-face contact with customers, or employ less than 10 workers – highlighting growing tensions over Prime Minister Benjamin Netanyahu’s handling of the pandemic, which is set to see Israel’s economy shrink this year for the first time in nearly two decades.

“The economy is breaking down, people’s hope is breaking down,” said Barelko, speaking in the Tel Aviv restaurant he runs, now empty of customers. “If the government does not give us the opportunity to live and to provide for our families, we’ll do it ourselves.”

Thousands of people have taken to the streets across Israel for almost daily protests that have built up since July, demanding Netanyahu resign over his handling of the crisis and over corruption charges he faces in court, which he denies.

The country, with a population of nine million, has reported nearly 280,000 COVID-19 cases and more than 1,800 deaths.

Schools and most offices, shops and restaurants are closed, unless they provide “vital services” such as supermarkets, pharmacies and banks, and people must stay within a kilometre from their home – harsher restrictions than in many other countries fighting a second wave.

Netanyahu had wide public

Read the rest